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INVITED COMMENTARY
Joseph L. Mills, MD, Tucson, Ariz
The report by Nguyen and colleagues analyzed quality of life
(QOL) data from participants in the PREVENT III trial. Details of
this trial have been previously described.1 Although a negative
trial, PREVENT III is nonetheless significant because it is one of
the largest prospective trials to date related to lower extremity
bypass (LEB) for critical leg ischemia (CLI). QOL issues are
important, and baselines for traditional therapies such as LEB
should be established to allow comparison with alternative, less-
invasive options.
The authors administered validated, disease-specific VascuQol
questionnaires to 1404 patients undergoing LEB for CLI in 83
centers. They concluded that “patients with CLI have a low QOL
at baseline that is improved at 3 and 12 months following LEB.”
QOL improvements were lower in diabetic patients and those
experiencing graft-related events (occlusion or stenosis). They
further concluded that “successful revascularization can be ex-
pected to improve QOL in patients with CLI with benefits sus-
tained to at least one year.”
Although I generally agree with the authors’ conclusions,
there are some problems. The QOL survey response rate was only
61% at 3 months and 52% at 1 year. These relatively low response
rates undoubtedly contribute to a systematic overestimation of the
QOL in CLI patients undergoing LEB. Patients with adverse
outcomes and those who recovered poorly, disappeared into nurs-
ing homes, and were therefore difficult to contact were more likely
to be survey nonresponders. In fact, the authors noted that non-
whites, diabetics, and patients experiencing graft-related events
were more likely to be survey nonresponders; furthermore, by
multivariable analysis, diabetes and graft-related events were asso-
ciated with decreased QOL at 1 year. Patients who required
amputation were significantly less likely to complete surveys. Thus,
it seems probable that the authors’ analysis paints an overly rosy
picture of LEB QOL outcomes. A more cautious interpretation of
their data is that because of inadequate survey responses at 1 year
and the negative effect of graft failure and amputation that oc-
curred in a significant number of patients, the QOL in the com-
plete cohort of LEB patients is likely to be significantly lower than
that suggested by the data set available for review in this article.
The QOL data reported here are actually more reflective of the
outcome of successful LEB. A similar, parallel conclusion actually
was reported from the BASIL trial, a prospective randomized trial
of open LEB vs percutaneous transluminal angioplasty (PTA) for
CLI. The BASIL trial participants noted that if the patient had a
patent graft at 2 years and was still alive with an intact leg, he or she
subsequently fared better with surgery than with PTA.2 The prob-
lem is that when we initially assess patients for intervention, we do
not know whether they will be alive at 2 years, and we also cannot
accurately predict which patients are likely to have a graft-related
event or amputation.
There are many issues the authors chose not to address in this
article; I hope they will release these issues in larger quanta in
future publications. Particularly, is QOL for patients undergoing
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revision of a patent graft better than for those undergoing revision
for graft occlusion? Additionally, is QOL affected by whether the
patient undergoes PTA or open revision for a graft stenosis? A
purported advantage of duplex surveillance is that it is less morbid
to revise a patent graft than an occluded one; many also believe that
graft PTA is less morbid than open revision. I wish the authors had
analyzed these issues in this study.
In sum, this is an important study. Qualify of life should be a
major end point of vascular and endovascular procedures. Future
studies will need to investigate the effect of diabetes and graft-
related events, as well as bypass failure and major limb amputation,
on the overall QOL in a large series of patients with CLI. If we
could identify more specific predictors of such adverse events,
perhaps we could avoid major LEB in individuals likely to fare
poorly and limit bypass to patients most likely to benefit.
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